axsome therapeutics initiates focus phase 3 trial of solriamfetol for the treatment of attention deficit hyperactivity disorder (adhd) in adults
FOCUS is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol…